Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)

Not Applicable

• Conditions: Prostate Cancer
• Interventions: Biological: Blood sample

• Registration Number: NCT04581109
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

The use of liquid biopsy could be the key for precision medicine. Circulating tumor cells (CTCs) are the most studied circulating biomarkers used to assess the metastatic process and they have shown their clinical validity and utility in cancer patients. However, their detection and capture are still a challenge as they are very rare in the bloodstream. In this clinical trial named "EPIDROP", the investigators will use an innovative device called EPIDROP (for EPIspot in a DROP) in metastatic prostate cancer. EPIDROP is a completely new technology answering to biological and clinical questions by proposing a procedure detecting the functional subset of prostatic CTCs at the single cell level. The investigators will stain cells in the sample for EpCAM, PSMA, CD45 before to encapsulate them one by one in microdroplets and measure the PSA secretion by only the viable CTCs. This study aims to demonstrate the non-inferiority of the EPIDROP compared to the CellSearch system.

Detailed Description

Methods :

One hundred patients with a metastatic prostate cancer will be recruited plus 50 healthy donors. Twenty ml of blood will be drawn : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP. Patients will be followed for 18 months.

Samples from fifty control subjects will be provided by the Etablissement Français du Sang.

Study Timeline

• Study First Submitted: 2020-10-02
• Study First Submitted QC: 2020-10-02
• Study First Posted: 2020-10-09
• Status Verified: 2021-05
• Study Start: 2021-05-27
• Last Update Submitted: 2021-06-02
• Last Update Posted: 2021-06-03
• Primary Completion: 2022-04
• Study Completion: 2023-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

• Non-metastatic prostate cancer in biological and/or clinical recurrence after hormone-suppression (nmCRPC)
• Other active or treated cancer less than 5 years old
• Be protected by law (guardianship or curatorship)
• Be deprived of liberty by administrative decision
• Not being affiliated to a social security scheme, or not being a beneficiary of such a plan
• Being in a period of exclusion from another protocol
• Inability to understand and/or respond to questionnaires
• Inability to understand the nature, purpose and methodology of the study
• Refusal to sign informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients with metastatic prostate cancer	Blood sample	-

Primary Outcome Measures

Name	Time	Method
EPIDROP technique sensitivity versus CellSearch system sensitivity	At 18 months	Proportion of true positive and false negative patients with a confidence interval
EPIDROP technique specificity versus CellSearch system specificity	At 18 months	Proportion of true negative and false positive healthy controls with a confidence interval

Trial Locations

Locations (2)

University Center, Hospital; 🇫🇷 Nîmes, France

University Hospital Center; 🇫🇷 Montpellier, Occitanie, France